BioXgen, a medical device company, has opened a Community Investment Round under Regulation Crowdfunding to advance development of its cardiac patch designed to prevent post-operative atrial fibrillation (POAF), the most common complication following open-heart surgery. This development matters because POAF affects approximately 50 percent of the 500,000 Americans who undergo open-heart surgery annually, significantly increasing risks of stroke, recurrent atrial fibrillation, kidney failure, and death, while costing the U.S. healthcare system approximately $9 billion each year.
The cardiac patch is placed directly on the heart's surface during surgery, with pre-clinical data published in Circulation showing POAF rates dropping from about 50% to under 5 percent—a tenfold reduction. Unpublished data from over 200 additional patients show similar results. The company has completed its Q-submission to the FDA and is pursuing clearance through the 510(k) pathway, targeting regulatory approval within 18 months if funding needs are met, with the goal of establishing the device as standard of care within 36 to 48 months.
The investment opportunity is structured as a Regulation Crowdfunding offering hosted by DealMaker Securities, with investments starting at $500, allowing retail investors to participate in a medical device category traditionally reserved for institutional capital. BioXgen's founders include Dr. David Skinner, President and CEO, who previously built and exited a medical company at 10x valuation, and Dr. John P. Konhilas, Chief Science Officer, a former physiology professor with 30 years of cardiac research experience and 11 patents. The founders will present their investment pitch during a live webinar on April 7, 2025, with registration available at https://dnagency.lpages.co/bioxgen-investor-presentation/.
The implications of this development extend beyond investment opportunity to potential transformation of post-surgical care. If successful, the cardiac patch could address a critical gap in cardiac surgery where no FDA-cleared prevention device currently exists, potentially reducing healthcare costs, improving patient outcomes, and setting a new standard for post-operative management. The company's regulatory strategy and clinical data position it to potentially impact how 250,000 annual patients recover from open-heart procedures. Prospective investors can review the offering details at https://invest.bioxgen.life/, where BioXgen has filed a Form C with the Securities and Exchange Commission, available at https://invest.bioxgen.life/.
